NEWTON, Mass.--(EON: Enhanced Online News)--Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral protein therapeutics to patients with serious renal, urologic, and orphan diseases, announced today that Alexey Margolin, Ph.D., President and Chief Executive Officer of Allena, will provide a corporate presentation at the 35th Annual J.P. Morgan Healthcare Conference at 8:00 a.m. PST (11:00 a.m. EST), on Thursday, January 12, 2017, at the Westin St. Francis Hotel in San Francisco.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral protein therapeutics to patients with serious renal, urologic, and orphan diseases. Allena is currently conducting a Phase 2 program for its lead product candidate, ALLN-177, in patients with hyperoxaluria. The company’s technological approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by degrading toxic metabolites, without being absorbed into the bloodstream. Led by a proven management team with deep expertise in protein therapeutic design and development, Allena is committed to bringing breakthrough new treatments to patients with unmet medical needs. Based in Newton, MA, the company is supported by a top-tier investor syndicate including Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners, HBM Partners, Pharmstandard International S.A., Partner Fund Management, Fidelity Management & Research Company, and other investors. For more information, please visit www.allenapharma.com.